This is the talk page for discussing improvements to the Ceftaroline fosamil article. This is not a forum for general discussion of the article's subject. |
Article policies
|
Find medical sources: Source guidelines · PubMed · Cochrane · DOAJ · Gale · OpenMD · ScienceDirect · Springer · Trip · Wiley · TWL |
![]() | Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Ceftaroline fosamil.
|
![]() | A fact from Ceftaroline fosamil appeared on Wikipedia's Main Page in the Did you know column on 30 October 2009 (check views). The text of the entry was as follows:
| ![]() |
![]() | This article is rated C-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | |||||||||||||||||||||||
|
Untitled
editLooking at the data in the DrugBox some of it appears to be for the acetate salt but this does not match the structure in the image. The InChI and SMILES currently match the image. It would be good to clarify whether the acetate should be included or not. --The chemistds (talk) 21:23, 28 April 2012 (UTC)
Spectrum of activity - sources
editThis statement: "It retains the activity of later-generation cephalosporins having broad-spectrum activity against Gram-negative bacteria" MUST be sourced. From my understanding, ceftaroline specifically was not effective against Gram negative organisms. However, if you have evidence to dispute that, then please make an edit. Thank you so much! — Preceding unsigned comment added by Aglo123 (talk • contribs) 03:07, 26 February 2018 (UTC)
- Update: I was wrong, sort of. It is somewhat effective against Gram negatives, but not nearly as well as the fourth-generation cephalosporins. Aglo123 (talk) 03:26, 26 February 2018 (UTC)
Clinical Use
editThis sentence "Ceftaroline is a novel cephalosporin with activity against MRSA with phase III clinical trials for complicated skin and skin structure infections with reported non-inferior efficacy against MRSA compared to vancomycin and aztreonam" is odd because it reads that ceftaroline is noninferior to vancomycin as well as aztreonam for activity against MRSA, but aztreonam is not used for MRSA -- it is only used for gram negatives. And Aztreonam kills pseudomonas aeruginosa as ceftaroline doesn't. Maybe just a rewording necessary. Also, sorry if I am doing this talk page wrong as I am still quite new! Tragicmonsters (talk) 02:56, 22 August 2019 (UTC)